Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053508 · ClinicalTrials.gov registry record · Phase 2
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT00053508 is a Phase 2 study that was terminated before completion, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 274 participants.
The verdict
NCT00053508, a Phase 2 study, was terminated before completion, sponsored by Sanofi Pasteur, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
Interventions
- BIOLOGICAL ACAM1000
- BIOLOGICAL vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053508
The ClinicalTrials.gov registry entry for NCT00053508 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ACAM1000 is the first listed.
NCT00053508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053508 about?
NCT00053508 is a clinical study titled "Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination". The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
What is the current status of trial NCT00053508?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2002-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00053508?
The interventions under investigation include: ACAM1000 (BIOLOGICAL), vaccinia virus (calf lymph) smallpox vaccine: Dryvax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00053508?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.